News Author: Jennifer Smith Publish date: June 11, 2019
Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.
News Author: Jennifer Smith Publish date: June 11, 2019
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of patient...
News Author: Jennifer Smith Publish date: June 8, 2019
CHICAGO – Complete response rates were higher among patients who received olanzapine plus standard therapy.
News Author: Jennifer Smith Publish date: June 6, 2019
CHICAGO – In a phase 1b trial of pembrolizumab, the 5-year OS rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients, ...
News Author: Jennifer Smith Publish date: June 1, 2019
CHICAGO – Patients who received SC-PEG had similar serum asparaginase activity, toxicities, and survival as pati...
News Author: Jennifer Smith Publish date: June 1, 2019
CHICAGO – CPX-351 followed by fludarabine, cytarabine, and filgrastim produced an overall response rate of 81%.<...
News Author: Jennifer Smith Publish date: May 31, 2019
Nearly a quarter of the patients screened as part of the National Cancer Institute–Children’s Oncology Group Pediatric MATCH trial have been matche...
News Author: Jennifer Smith Publish date: May 23, 2019
Entrectinib produced responses in patients who had fusions or mutations in target genes.
Article Author: Jennifer Smith Publish date: May 20, 2019
Four researchers won funding via the NCCN Young Investigator Awards, and eight researchers will receive funding from the Andrew Sabin Family Founda...
News Author: Jennifer Smith Publish date: May 17, 2019
NEW ORLEANS – NGS of peripheral blood proved at least as effective as flow cytometry for assessing MRD in children and young adults with B-ALL who ...
News Author: Jennifer Smith Publish date: May 17, 2019
The lowest dose of oxaliplatin and capecitabine proved noninferior to two higher doses in a study of older and frail patients with advanced gastroe...
News Author: Jennifer Smith Publish date: May 16, 2019
At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66% ...
News Author: Jennifer Smith Publish date: May 16, 2019
A balanced, low-fat diet was associated with a 21% lower risk of death from breast cancer in a randomized study.
News Author: Jennifer Smith Publish date: May 14, 2019
NEW ORLEANS – Quality of life was the most common reason for starting second-line therapy in a cohort of children with immune thrombocytopenia.
News Author: Jennifer Smith Publish date: May 12, 2019
NEW ORLEANS – “What we see in childhood AML is a lot different than what we see in adult AML, and this challenges the paradigm that we have traditi...
